OncoMatch/Clinical Trials/NCT06541847
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Is NCT06541847 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HLX-1502 for neurofibromatosis type 1.
Treatment: HLX-1502 — The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: HLX-1502 (HLX-1502)
Prior treatment with HLX-1502 for a PN
Cannot have received: MEK inhibitor
MEK-inhibitors
Cannot have received: tyrosine kinase inhibitor
other drugs in the TKI class
Cannot have received: myelosuppressive chemotherapy
Myelosuppressive chemotherapy
Cannot have received: hematopoietic growth factors
Hematopoietic growth factors
Cannot have received: biologic (anti-neoplastic agent)
Biologic (anti-neoplastic agent)
Cannot have received: investigational drug
Investigational Drugs
Cannot have received: systemically administered anti-neoplastic agent
Any other systemically administered anti-neoplastic agent
Cannot have received: radiation therapy
Radiation therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital Colorado · Aurora, Colorado
- Children's National Hospital · Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify